APP-London model

Key characteristics


Progressive total plaque load (an anti-Aβ antibody) and dense plaque load (Thioflavin S) in the subiculum as measured by IHC (mean ± SEM, N = 5-9).


The London mutation [V717] is a preferred model for anti-BACE1 approaches. The Swedish mutation might result in an aberrant subcellular localization of APP (Jacobsen et al., 2014).


Long term potentiation deficit (induced by a high frequency stimulation) in the CA1 region of the hippocampus in 8 month old APP[V717] animals and age-matched littermates can be restored with a therapeutic compound (mean ± SEM, n = 5 per group).

Interested to see more data?

We have a more extensive datapackage available. Contact us at cro[at] to set up a meeting and discuss how we translate your mechanism of action into an effective study design.


Describing papers:

Therapeutic intervention papers: